European Drugmakers Sanofi And Gsk Strike 2 1 Billion Deal With U S Sanofi has licensed joint commercial rights to novavax’s covid 19 vaccine and will work with the biotech on the development of combined flu covid shots in a deal worth up to $1.2 billion. Sanofi and novavax have announced a licensing agreement worth over $1.2bn to co commercialise novavax’s covid 19 vaccine and develop combination vaccines for covid 19 and influenza.
Sanofi And Glaxosmithkline Snag Biggest Coronavirus Vaccine Deal Yet Starting this year, sanofi will record sales of the covid 19 shot vaccine nuvaxovid, paying novavax royalties on those sales. the deal is more than a financial lifeline. Novavax, which had licensed the rights for nuvaxovid last year for up to $1.2 billion, expects royalties from the shot to increase significantly in the 2026 season, as sanofi leads. Novavax in may had signed a deal worth at least $1.2 billion with sanofi to hand over the rights to sell its vaccines in several markets, including the united states and europe, in exchange for a stake in the company. "we're excited that sanofi has recognized the potential of a pandemic influenza vaccine candidate that contains novavax's validated matrix m ® adjuvant," said john c. jacobs, president and chief executive officer, novavax.
107290091 1692714680092 Gettyimages 1239401928 Prvk0621 Jpeg V Novavax in may had signed a deal worth at least $1.2 billion with sanofi to hand over the rights to sell its vaccines in several markets, including the united states and europe, in exchange for a stake in the company. "we're excited that sanofi has recognized the potential of a pandemic influenza vaccine candidate that contains novavax's validated matrix m ® adjuvant," said john c. jacobs, president and chief executive officer, novavax. Under the terms of the licensing agreement: novavax will receive an upfront payment of $500 million and up to $700 million in development, regulatory and launch milestones, up to $1.2 billion in total. Sanofi has licensed joint commercial rights to novavax’s covid 19 vaccine and will work with the biotech on the development of combined flu covid shots in a deal worth up to $1.2. Shares in novavax almost doubled after sanofi struck a licensing deal worth up to $1.2bn to commercialise the struggling covid 19 vaccine maker’s coronavirus jab and use the technology to. Paris: sanofi has entered into a co exclusive licensing agreement with novavax, a biotechnology company headquartered in maryland, us to develop a diverse portfolio of best in class vaccines.
Comments are closed.